Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Hypertension. 2014 Mar 31;63(6):1345–1353. doi: 10.1161/HYPERTENSIONAHA.113.02804

Fig. 6. Therapeutic effect of ASC-J9® in reducing atherosclerosis by inhibiting monocyte infiltration.

Fig. 6

a. ASC-J9® effects on plaque formation in mice. WT-LDLR−/− mice fed with HFD for 8 weeks were injected with ASC-J9® (75 mg/Kg body weight) every other day for another 8 weeks with continued HFD treatment. Quantitation is shown below images, *p<0.05 b. IHC staining results of AR in aortic tissues of vehicle and ASC-J9® treated mice. c. Mac-3 IHC staining results in aortic tissues of vehicle and ASC-J9® treated mice. For both b and c, magnification 100x, insets, 400x. Arrowheads indicate positive stained cells. Qnantitation is shown below images, **p<0.01.